After the U.S. Food and Drug Administration recently approved an investigational new drug application for Anavex 2-73, Anavex Life Sciences is proceeding with its Phase 2 clinical trial of the medication in Rett syndrome patients, the company announced. The trial (NCT03758924) will assess the safety, tolerability,…
News
Recent Posts
- The most difficult conversation I have ever had
- Experts recommend Daybue as first-line therapy for Rett syndrome
- Guest Voice: Like stars, the grief of losing my sister is always present
- The spa, the snow, and the Make-A-Wish gift that keeps giving
- Powder form of Rett treatment Daybue now widely available in US
- Opening day, and that time a ribbon wasn’t the only thing that was cut
- Fenfluramine reduces hard-to-treat seizures in 3 girls with Rett syndrome
- ‘Spread the Word Day’ reminds me of our own encounter with the R-word
- New study supports switching between Daybue liquid and powder forms
- Leaky blood vessels in the brain linked to Rett syndrome: Study